Benchmarking Disease Modifying Therapies for Alzheimer's Disease Using a Quantitative Systems Pharmacology Model

The link between Alzheimer’s disease (AD) pathological mechanisms and AD biomarkers was modeled to assess the potential impact of therapeutic interventions. A Quantitative Systems Pharmacology platform was used to model amyloid an tau pathologies between compartments (brain, cerebrospinal fluid, plasma) based on transport pathways. The model was created using observed and simulated data from four anti-amyloid antibodies (solanezumab, crenezumab, gantenerumab, aducanumab) and an anti-tau antibody (semorinemab).

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.